IDEXX Laboratories, Inc. (IDXX) CEO Sells $2,788,380.00 in Stock
IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the sale, the chief executive officer now directly owns 1,043,034 shares of the company’s stock, valued at approximately $161,576,396.94. The sale was disclosed in a filing with the SEC, which is available at this link.
Jonathan W. Ayers also recently made the following trade(s):
- On Tuesday, August 8th, Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock. The shares were sold at an average price of $155.22, for a total transaction of $2,793,960.00.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at 150.44 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $102.45 and a 1-year high of $173.01. The stock has a market cap of $13.13 billion, a PE ratio of 51.75 and a beta of 0.49. The stock has a 50 day moving average of $160.14 and a 200 day moving average of $156.81.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.10. The business had revenue of $508.90 million during the quarter, compared to analyst estimates of $502.44 million. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The company’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.74 earnings per share. Equities research analysts forecast that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.
IDEXX Laboratories declared that its board has authorized a share repurchase plan on Wednesday, May 3rd that permits the company to repurchase 3,000,000 shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.
Several brokerages recently issued reports on IDXX. Aegis began coverage on shares of IDEXX Laboratories in a research note on Wednesday, May 31st. They set a “sell” rating and a $118.00 price objective for the company. They noted that the move was a valuation call. Stifel Nicolaus upped their price objective on shares of IDEXX Laboratories from $150.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, May 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price objective (up previously from $165.00) on shares of IDEXX Laboratories in a research note on Friday, April 28th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $187.00 price objective for the company in a research note on Monday, May 29th. Finally, BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. IDEXX Laboratories currently has a consensus rating of “Hold” and a consensus target price of $173.80.
Several institutional investors have recently bought and sold shares of IDXX. Mn Services Vermogensbeheer B.V. raised its position in IDEXX Laboratories by 5.7% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,391 shares of the company’s stock worth $346,000 after buying an additional 128 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in IDEXX Laboratories during the first quarter worth $336,000. Columbus Circle Investors raised its position in IDEXX Laboratories by 5.9% in the first quarter. Columbus Circle Investors now owns 570,867 shares of the company’s stock worth $88,262,000 after buying an additional 31,586 shares in the last quarter. Hartford Investment Management Co. raised its position in IDEXX Laboratories by 614.2% in the first quarter. Hartford Investment Management Co. now owns 21,018 shares of the company’s stock worth $3,250,000 after buying an additional 18,075 shares in the last quarter. Finally, Barometer Capital Management Inc. purchased a new position in IDEXX Laboratories during the first quarter worth $14,978,000. 89.42% of the stock is owned by institutional investors and hedge funds.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.